MASSACHUSETTS GENERAL HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $762.5M
- Transactions
- 17,408
- Companies
- 40
- Average per transaction
- $43,804
Who reported the payments
| Zimmer Biomet | $215,882,918 |
| Takeda Pharmaceuticals U.S.A., Inc. | $129,982,674 |
| Pfizer | $27,698,847 |
| GE HealthCare | $20,603,513 |
| E.r. Squibb & Sons, L.L.C. | $20,459,555 |
| Amgen | $19,922,114 |
| Merck | $16,485,268 |
| AbbVie | $15,648,404 |
| Genentech, Inc. | $15,456,055 |
| Biogen | $14,109,229 |
| Illumina, Inc. | $12,771,913 |
| AstraZeneca | $11,652,376 |
| Stryker | $11,457,634 |
| Janssen Research & Development, LLC | $9,966,399 |
| Beckman Coulter, Inc. | $9,908,107 |
| Boston Scientific | $9,212,499 |
| Sanofi US Services Inc. | $9,001,274 |
| Tanabe Pharma America, Inc. | $8,884,172 |
| Gilead | $7,429,182 |
| Biohaven Pharmaceutical Holding Company Ltd. | $6,431,502 |
| Edwards Lifesciences | $5,990,186 |
| Siemens Medical Solutions USA, Inc. | $4,761,271 |
| Servier Bioinnovation | $4,688,421 |
| Biohaven Pharmaceuticals, Inc. | $3,803,348 |
| Regeneron | $3,608,046 |
| Beigene, Ltd. | $3,543,413 |
| Modernatx, Inc. | $3,524,647 |
| Vertex | $3,287,001 |
| Boehringer Ingelheim | $3,251,664 |
| Eli Lilly | $3,221,333 |
| Boehringer Ingelheim International GmbH | $3,033,199 |
| Astrazeneca UK Limited | $2,951,486 |
| Medtronic | $2,888,093 |
| Terumo Medical Corporation | $2,866,666 |
| Transmedics, Inc. | $2,789,729 |
| Astellas Pharma Inc | $2,584,598 |
| Canon Medical Systems Corporation | $2,483,875 |
| Omnilife Science, Inc | $2,419,387 |
| Jazz Pharmaceuticals Inc. | $2,324,512 |
| Incyte Corporation | $2,316,059 |